Tradestie Institutional Equity Comparison Engine

FDMT vs CRSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

FDMT Overall Edge

FDMT Captures Institutional Edge (3โ€“1 Pillars ยท 3โ€“7 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to 4D Molecular Therapeutics, Inc. Common Stock (FDMT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
FDMT N/M vs CRSP 23.4x Fwd P/E
Growth & Margin Winner FDMT
Op Margin -222.7% vs -2058.6% ยท YoY +4505.6% vs +1325.1%
Momentum & Technical Winner FDMT
1Y +13.3% vs -20.5% ยท 52W Pos 47% vs 1%
Options & Structure Winner FDMT
BREAKDOWN (10th %ile IV) vs BREAKDOWN (52nd %ile IV)
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FDMT +13.33% CRSP -20.54% Spread: +33.87 pp (FDMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period FDMT Revenue CRSP Revenue FDMT Op. Margin CRSP Op. Margin Margin Edge
FY2018 N/A $0M N/A -5087.8% CRSP
FY2019 $10M $290M -729.4% 16.1% CRSP
FY2020 $10M $0M -424.0% -49295.5% FDMT
FY2021 $20M $910M -395.5% 40.8% CRSP
FY2022 $0M $0M -3516.5% -56190.4% FDMT
FY2023 $20M $370M -544.6% -60.0% CRSP
FY2024 $0M $40M -507678.4% -1250.4% CRSP
FY2025 $90M $0M -187.2% -18933.6% FDMT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FDMT (3) vs CRSP (7)
Institutional Metric FDMT CRSP Criterion Row Winner
Market Capitalization Scale $669.3M $4.1B Larger Scale CRSP
Trailing P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Forward P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Revenue Growth (YoY) Growth +4505.6% +1325.1% Higher Growth FDMT
Operating Margin (TTM) Profitability -222.7% -2058.6% Higher Margin FDMT
Net Profit Margin Profitability -208.6% 0.0% Higher Margin CRSP
Return on Equity (ROE) Capital Efficiency -56.7% -25.6% Higher ROE CRSP
52-Week Range Position Momentum 47% ($7โ€“$17) 1% ($40โ€“$63) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 1.89ฮฒ ยท 90% Vol 1.85ฮฒ ยท 60% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 48.6 / 100 (HOLD) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FDMT vs CRSP Buy Guide
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FDMT nor CRSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.